High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.

High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.

RAS and BRAF mutations impact treatment and prognosis of metastatic colorectal cancer patients (mCRC), but the knowledge is based on trial patients usually not representative for the general cancer population. Patient characteristics, treatment and efficacy according to KRAS, BRAF and MSI status wer...

Full description

Bibliographic Details
Main Authors: Halfdan Sorbye, Anca Dragomir, Magnus Sundström, Per Pfeiffer, Ulf Thunberg, Monica Bergfors, Kristine Aasebø, Geir Egil Eide, Fredrik Ponten, Camilla Qvortrup, Bengt Glimelius
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4484806?pdf=render

Internet

http://europepmc.org/articles/PMC4484806?pdf=render

Similar Items